About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/25/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/25/2021.

Reliability and Validity of the Turkish Version of the Multiple Sclerosis Knowledge Questionnaire

Clinicaltrials.gov identifier NCT03927092

Recruitment Status Completed

First Posted April 25, 2019

Last update posted April 29, 2019

Study Description

Brief summary:

Multiple Sclerosis Knowledge Questionnaire (MSKQ) is a 25-item self administered questionnaire assessing a patient's level of knowledge regarding multiple sclerosis (MS). Turkish translation of the questionnaire was prepared and participants in the annual patient education seminar in the investigators' university hospital were asked to answer these questions before and after the seminar.Their results were analysed to assess their level of knowledge about their disease.

  • Condition or Disease:Multiple Sclerosis
  • Intervention/Treatment: Other: Multiple Sclerosis Knowledge Questionnaire
  • Phase: N/A
Detailed Description

Multiple sclerosis knowledge questionnaire was developed in Italy (1) and was reported to be useful in measuring patients' level of knowledge about their disease. The English version of the questionnaire was translated into Turkish by three physicians than back translated into English by two separate linguists. Initially 5 MS patients were asked to answer this first version of the questionnaire and report any difficulties in understanding the items. Their feedback was used to give the questionnaire its final shape. For the validation stage, patients that were diagnosed as having MS and who attended the annual MS patient education seminar were enrolled into the study. They answered the questions twice, before and after the seminar. Their answers were analysed to measure their level of knowledge about their disease.

Study Design
  • Study Type: Observational
  • Actual Enrollment: 58 participants
  • Observational Model: Case-Only
  • Time Perspective: Cross-Sectional
  • Official Title: Reliability and Validity of the Turkish Version of the Multiple Sclerosis Knowledge Questionnaire
  • Actual Study Start Date: May 2016
  • Actual Primary Completion Date: May 2016
  • Actual Study Completion Date: May 2016
Groups and Cohorts
Groups/Cohorts Intervention/treatment
: Multiple Sclerosis patients
Patients that attended an annual patient education seminar at the investigators' university hospital were asked to fill out the Turkish version of the Multiple Sclerosis Knowledge Questionnaire
Other: Multiple Sclerosis Knowledge Questionnaire
A 25-item self-administered questionnaire
Outcome Measures
  • Primary Outcome Measures: 1. reliability of the questionnaire [ Time Frame: 1 day ]
    Internal consistency was evaluated by the coefficient alpha (α) or Cronbach's coefficient, and if the Cronbach's coefficient value was greater than 0.7, it was considered as an acceptable internal consistency
  • Secondary Outcome Measures: 1. Number of correct answers [ Time Frame: 1 day ]
    To assess the distribution of correct and false answers and the levels of significance, Chi-square test was used. To compare the two questionnaires answered by the same patient before and after the seminar Wilcoxon signed-rank test was used.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
  • Sampling Method: Non-Probability Sample
  • Study Population: Patients diagnosed as having multiple sclerosis.
Criteria

Inclusion Criteria:

- Diagnosed as having Multiple Sclerosis

- Attends the annual patient education seminar at the investigators' university hospital

- Older than 18 years of age

- Can read and write

Exclusion Criteria:

- Does not accept to answer the questionnaire

- Unable to answer the questions due to a cognitive impairment

Contacts and Locations
Contacts
Locations
Sponsors and Collaborators

Ege University

Investigators

Principal Investigator: Ece Cinar, M.D. Ege University School of Medicine

Study Director: Yesim Akkoc, M.D. Ege University School of Medicine

Principal Investigator: Funda Calis, M.D. Ege University School of Medicine

Principal Investigator: Musa Baklaci, M.D. Ege University School of Medicine

Principal Investigator: Ozgul Ekmekci, M.D. Ege University School of Medicine

Principal Investigator: Ayse N Yuceyar, M.D. Ege University School of Medicine

More Information